Evidence map›Paper›PMID 25609807›Full record

ArticleJournal of virology2015

Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.

Julie Delaloye, Abdelali Filali-Mouhim, Mark J Cameron, Elias K Haddad, Alexandre Harari, Jean-Pierre Goulet, Carmen E Gomez, Beatriz Perdiguero, Mariano Esteban, Giuseppe Pantaleo and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Julie DelaloyeInfectious Diseases Service, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland.
Abdelali Filali-MouhimVaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA.
Mark J CameronVaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA.
Elias K HaddadVaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA.
Alexandre HarariDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland.
Jean-Pierre GouletVaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA.
Carmen E GomezCentro Nacional de Biotecnología, CSIC, Madrid, Spain.
Beatriz PerdigueroCentro Nacional de Biotecnología, CSIC, Madrid, Spain.
Mariano EstebanCentro Nacional de Biotecnología, CSIC, Madrid, Spain.
Giuseppe PantaleoDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland.
Thierry RogerInfectious Diseases Service, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland.
Rafick-Pierre SékalyVaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA.
Thierry CalandraInfectious Diseases Service, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland Thierry.Calandra@chuv.ch.
University of Lausanne · CHVaccine & Gene Therapy Institute of Florida · USCentro Nacional de Biotecnología · ESVaccine and Gene Therapy Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledNYVAC, a highly attenuated, replication-restricted poxvirus, is a safe and immunogenic vaccine vector. Deletion of immune evasion genes from the poxvirus genome is an attractive strategy for improving the immunogenic properties of poxviruses. Using systems biology approaches, we describe herein the enhanced immunological profile of NYVAC vectors expressing the HIV-1 clade C env, gag, pol, and nef genes (NYVAC-C) with single or double deletions of genes encoding type I (ΔB19R) or type II (ΔB8R) interferon (IFN)-binding proteins. Transcriptomic analyses of human monocytes infected with NYVAC-C, NYVAC-C with the B19R deletion (NYVAC-C-ΔB19R), or NYVAC-C with B8R and B19R deletions (NYVAC-C-ΔB8RB19R) revealed a concerted upregulation of innate immune pathways (IFN-stimulated genes [ISGs]) of increasing magnitude with NYVAC-C-ΔB19R and NYVAC-C-ΔB8RB19R than with NYVAC-C. Deletion of B8R and B19R resulted in an enhanced activation of IRF3, IRF7, and STAT1 and the robust production of type I IFNs and of ISGs, whose expression was inhibited by anti-type I IFN antibodies. Interestingly, NYVAC-C-ΔB8RB19R induced the production of much higher levels of proinflammatory cytokines (tumor necrosis factor [TNF], interleukin-6 [IL-6], and IL-8) than NYVAC-C or NYVAC-C-ΔB19R as well as a strong inflammasome response (caspase-1 and IL-1β) in infected monocytes. Top network analyses showed that this broad response mediated by the deletion of B8R and B19R was organized around two upregulated gene expression nodes (TNF and IRF7). Consistent with these findings, monocytes infected with NYVAC-C-ΔB8RB19R induced a stronger type I IFN-dependent and IL-1-dependent allogeneic CD4(+) T cell response than monocytes infected with NYVAC-C or NYVAC-C-ΔB19R. Dual deletion of type I and type II IFN immune evasion genes in NYVAC markedly enhanced its immunogenic properties via its induction of the increased expression of type I IFNs and IL-1β and make it an attractive candidate HIV vaccine vector. IMPORTANCE: NYVAC is a replication-deficient poxvirus developed as a vaccine vector against HIV. NYVAC expresses several genes known to impair the host immune defenses by interfering with innate immune receptors, cytokines, or interferons. Given the crucial role played by interferons against viruses, we postulated that targeting the type I and type II decoy receptors used by poxvirus to subvert the host innate immune response would be an attractive approach to improve the immunogenicity of NYVAC vectors. Using systems biology approaches, we report that deletion of type I and type II IFN immune evasion genes in NYVAC poxvirus resulted in the robust expression of type I IFNs and interferon-stimulated genes (ISGs), a strong activation of the inflammasome, and upregulated expression of IL-1β and proinflammatory cytokines. Dual deletion of type I and type II IFN immune evasion genes in NYVAC poxvirus improves its immunogenic profile and makes it an attractive candidate HIV vaccine vector.

Indexed as

Genetic VectorsAIDS VaccinesCells, CulturedGene Expression ProfilingHumansInterferon Type IInterleukin-1Leukocytes, MononuclearSequence DeletionAIDS VaccinesInterferon Type IInterleukin-1NYVAC-C vaccine

Identifiers

PMID25609807
PMCPMC4403427
OpenAlexW2054932185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.